AgomAb Therapeutics NV (AGMB) vs Altimmune (ALT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Altimmune is the larger company by market cap ($507.7 million vs $447.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | ALT |
|---|---|---|
| Share price | $9.08 | $2.61 |
| Market cap | $447.17M | $507.69M |
| 1-day change | -1.52% | +0.38% |
| YTD return | — | -27.70% |
| 1-year return | — | -34.75% |
| 5-year return | — | -78.27% |
| EPS (TTM) | $-2.08 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $6.44 |
| 52-week low | $7.97 | $2.55 |
| Distance from 52-week high | -49.05% | -59.47% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +314.87% | +555.56% |
| Average volume | 140.67K | 4.23M |
| Shares outstanding | 49.25M | 194.52M |
| Employees | 62 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
AGMB vs ALT FAQ
Which is bigger, AgomAb Therapeutics NV or Altimmune?
Altimmune (ALT) is larger, with a market capitalization of $507.69M compared with $447.17M for AgomAb Therapeutics NV (AGMB).
Are AgomAb Therapeutics NV and Altimmune in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for AgomAb Therapeutics NV and Biotechnology: Pharmaceutical Preparations for Altimmune.